Latham & Watkins Advises on AlloVir’s US$75 Million Public Offering of Common Stock

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, has announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of US$3.75 per share. The gross proceeds to AlloVir from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be US$75.0 million. All shares in the offering are to be sold by AlloVir. In addition, AlloVir has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about June 26, 2023, subject to customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a corporate team led by partners Nathan Ajiashvili and Alison Haggerty, with associates Roger Yarett, Lia-Michelle Keane, Jie Lin Nai, and Richard Dacher.